BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $ALNY readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07465224-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:ALN-4324 readout (P2) · Alnylam Pharmaceuticals $ALNY
DESCRIPTION:A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults W
 ith Type 2 Diabetes Mellitus\n\nPrimary completion date: 2027-05-28 (estim
 ated)\nPhase 2 · Cardio-Met · Type 2 Diabetes Mellitus (T2DM)\nEnrollmen
 t: 24 · Sites: 1\n\nPrimary completion = last participant's primary-endpo
 int data collected\; topline results usually follow weeks to months later.
  Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://t
 rialsonar.netlify.app/radar.html?nct=NCT07465224\nhttps://clinicaltrials.g
 ov/study/NCT07465224
URL:https://datacutoff.com/radar.html?nct=NCT07465224
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575308-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HMBeacon readout (P2) · Alnylam Pharmaceuticals $ALNY
DESCRIPTION:HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Ado
 lescent Female Patients With VWD and HMB\n\nPrimary completion date: 2027-
 06-30 (estimated)\nPhase 2 · Rare · Von Willebrand Disease (VWD)\, Heavy
  Menstrual Bleeding (HMB)\nEnrollment: 24 · Sites: 29\n\nPrimary completi
 on = last participant's primary-endpoint data collected\; topline results 
 usually follow weeks to months later. Sponsor-reported\, often an estimate
 . Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=
 NCT07575308\nhttps://clinicaltrials.gov/study/NCT07575308
URL:https://datacutoff.com/radar.html?nct=NCT07575308
CATEGORIES:Rare,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393712-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:cAPPricorn-1 readout (P2) · Alnylam Pharmaceuticals $ALNY
DESCRIPTION:A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid An
 giopathy\n\nPrimary completion date: 2027-08-09 (estimated)\nOriginally pl
 anned: 2027-07 (+1.3 months)\nPhase 2 · Cardio-Met · Cerebral Amyloid An
 giopathy\nEnrollment: 210 · Sites: 57\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06393712\nhtt
 ps://clinicaltrials.gov/study/NCT06393712
URL:https://datacutoff.com/radar.html?nct=NCT06393712
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
